Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference

Abstract
The Third Cambridge Conference on Innovations and Challenges in Renal Cancer, a symposium held in Cambridge, Massachusetts, June 27‐28, 2008, and chaired by Michael B. Atkins, was convened to discuss the current state of knowledge in the field, critique new data, stimulate communication among those involved in basic and clinical research, and offer recommendations for further study. Four main topics were discussed: genetics and molecular biology of renal cell cancer, staging and prognosis, systemic therapy, and correlative science and biomarkers in stage IV disease. The conference format combined brief presentations with extended periods of discussion. The conclusions and recommendations are summarized in this paper and presented in more detail in the individual papers that follow. Cancer 2009;115(10 suppl):2247‐51. © 2009 American Cancer Society.
Funding Information
  • Genentech, Novartis Pharmaceuticals, Pfizer, Inc., and Wyeth Pharmaceuticals
  • National Institutes of Health, National Cancer Institute, Center for Cancer Research
  • Bayer and Novartis
  • Bayer and Pfizer
  • Amgen, GlaxoSmithKline, Pfizer, and Wyeth